243 related articles for article (PubMed ID: 29984627)
1. Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab.
Keung YK; Hu EH
J Oncol Pharm Pract; 2019 Jul; 25(5):1261-1264. PubMed ID: 29984627
[TBL] [Abstract][Full Text] [Related]
2. Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding.
Dall'Olio FG; Sperandi F; Rihawi K; Gargiulo M; Melotti B; Brocchi S; Gelsomino F; Ardizzoni A
J Thorac Oncol; 2018 Dec; 13(12):e247-e248. PubMed ID: 30467045
[No Abstract] [Full Text] [Related]
3. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
[No Abstract] [Full Text] [Related]
4. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
5. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
[No Abstract] [Full Text] [Related]
6. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report.
Jiang R; Xu L; Huang Y; Fang C; Guo H; Li S; Wu J; Du Z
Pancreas; 2018 Sep; 47(8):e53-e54. PubMed ID: 30113432
[No Abstract] [Full Text] [Related]
7. Checkpoint Inhibitor-Induced Rejection of a Liver Allograft: A Combination of Acute T Cell-Mediated and Antibody-Mediated Rejection.
Lee BT; Horwich BH; Chopra S; Ahearn A; Han HH
Liver Transpl; 2019 Dec; 25(12):1845-1848. PubMed ID: 31408574
[No Abstract] [Full Text] [Related]
8. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
9. A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
Lee SY; Kim MH; Jang M; Park Y; Cho BC
Eur J Cancer; 2018 Nov; 104():104-107. PubMed ID: 30342309
[No Abstract] [Full Text] [Related]
10. New onset of psoriasis during nivolumab treatment for lung cancer.
Chujo S; Asahina A; Itoh Y; Kobayashi K; Sueki H; Ishiji T; Umezawa Y; Nakagawa H
J Dermatol; 2018 Mar; 45(3):e55-e56. PubMed ID: 29205470
[No Abstract] [Full Text] [Related]
11. Nivolumab-induced aplastic anemia: A case report and literature review.
Comito RR; Badu LA; Forcello N
J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
13. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
[No Abstract] [Full Text] [Related]
14. Papulopustular rosacea during nivolumab therapy of metastatic squamous cell esophageal carcinoma.
Gahoonia NK; Carrington AE; Chambers CJ; Sivamani RK
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755982
[TBL] [Abstract][Full Text] [Related]
15. [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].
Troyanova-Slavkova S; Eickenscheidt L; Dumann K; Kowalzick L
Hautarzt; 2018 Aug; 69(8):674-680. PubMed ID: 29330579
[TBL] [Abstract][Full Text] [Related]
16. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.
Shah KM; Rancour EA; Al-Omari A; Rahnama-Moghadam S
Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142712
[TBL] [Abstract][Full Text] [Related]
17. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
18. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
[No Abstract] [Full Text] [Related]
19. Linear bullous lichen planus associated with nivolumab.
Biolo G; Caroppo F; Salmaso R; Alaibac M
Clin Exp Dermatol; 2019 Jan; 44(1):67-68. PubMed ID: 29920744
[No Abstract] [Full Text] [Related]
20. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
Edahiro R; Shiroyama T; Hijiki S; Nojima S; Shirai Y; Koyama S; Kumanogoh A
Lung Cancer; 2020 Feb; 140():116-117. PubMed ID: 31848027
[No Abstract] [Full Text] [Related]
[Next] [New Search]